Participants will be required to complete one set of online survey instruments, consisting of four unique surveys, at eight critical points throughout their graduate program. Early in the study, participants will also be asked to complete a one-time Participant Demographics form. The four surveys include the Brief Symptom inventory 18(BSI 18), the Financial Anxiety Scale, a multidimensional scale of perceived stress, as well as the Jefferson Empathy Scale. The financial anxiety scale and the perceived stress scale will each take less than five minutes to complete. Both the financial anxiety scale and the perceived stress scale will be administered through CMU's REDCap system (Research Electronic Data Capture) managed by the IT division of Central Michigan University. The BSI 18 will take approximately 3 to 5 minutes to complete and will be administered through the manufacturer called Pearson using Q-global. The final survey is the Jefferson empathy scale that will be administered through a link generated by Jefferson Medical School. Participants will receive a separate electronic email invitation from Q-global to complete the BSI18. Administration of the four online surveys will take place at the endpoint of the first semester and at the midpoint of each consecutive semester until the sixth semester, along with two additional administrations at the end of semesters four and six.
The study will collect information from patients who have received treatment for posttraumatic stress disorder (PTSD) about their thoughts, preferences, and suggestions for ways to incorporate mobile technologies into PTSD treatment.
Behavioral health problems among Veterans have raised awareness of the critical need for more reliable, effective, and accessible ways to recognize those in need, direct them to help, and ensure that they receive the best evidence-based care available. AboutFace is a novel peer education program that features the personal stories of Veterans and is designed to improve Veterans' likelihood of engaging in PTSD specialty care. Using a randomized controlled study design we propose to compare the efficacy of AboutFace relative to standard care for improving treatment engagement and outcomes. Additional data from VA providers will provide valuable information on wide scale implementation and dissemination of AboutFace. If AboutFace increases access of services, data will have broad implications for overcoming barriers to care for Veterans with PTSD and other stigmatized conditions.
Objectives: The aim of the study is to evaluate the efficacy and safety of DTMS for the treatment of PTSD.
Patient Population: 176 male and female subjects, 22-68 years of age, currently diagnosed with PTSD according to the DSM-V criteria.
Structure: A randomized, controlled, prospective, 9 week, double blind, multicenter study.
Blinding: The treatment administrator, study rater, all study personnel and patients will be blinded to the treatment being administered.
Concurrent Control: The study group will receive active DTMS treatment and the control group will receive inactive, sham treatment.
We are currently recruiting women and men ages 18-70 who have had trauma experience and who use alcohol. This research study includes 12 weekly therapy sessions as well as random assignment to receive either the study medication or placebo.
The study will examine the ability of N-acetylcysteine (NAC), an antioxidant/dietary supplement, to reduce the severity of alcohol cravings and withdrawal as well as symptoms associated with PTSD.
As a result of sustained operations in Afghanistan and Iraq, there are an increasing number of U.S. military Veterans with substance use disorders and comorbid posttraumatic stress disorder (PTSD). If left untreated, individuals with substance use disorders and PTSD are at increased risk for developing other mental health problems (e.g., depression, anxiety), suicidal ideation and attempts, medical problems, reduced resiliency and military readiness, vocational problems, and family/social impairment.Determine the benefits of N-acetylcysteine (NAC) in treating alcohol use disorder and comorbid post-traumatic stress disorder (PTSD) among military Veterans.
The current study will modify an already existing therapy for individuals with substance use disorders to address PTSD in women enrolled in SUD treatment who suffer with both PTSD and SUD. Mindfulness meditation has been shown to help individuals to cope with stress and regulate emotions. Through meditation practice women will experience less distress related to PTSD symptoms and reduced substance use in response to emotional triggers. Women enrolled in intensive SUD treatment at a community program will be randomized to receive either 8 weeks of 90 minute Mindfulness Based Relapse Prevention (MBRP) group sessions plus treatment as usual (TAU) or TAU alone. The MBRP group sessions will replace 90 minutes of TAU group therapy. Measures of feasibility of implementation, acceptance and adherence will be obtained. Preliminary efficacy for substance use and PTSD symptom severity will be measured at post treatment and at 3- and 6- months' follow-up.
The purpose of this study is to evaluate the effects of a medication (doxazosin) on reducing symptoms of posttraumatic stress disorder (PTSD) and substance use in Veterans. We will also examine the effects of doxazosin on brain activity at pre and post treatment.
Social stress often leads to drug craving and relapse in cocaine-dependent populations. Currently there are no FDA approved medications for the treatment of cocaine dependence. Therefore, biomedical research studies aimed at investigating the brain mechanisms responsible for controlling emotional responses to social stress could have a significant impact on the development of effective therapeutic treatment strategies for cocaine-dependent individuals.
The Sleep Research Data Repository (SRDR) aimed to systematically collect, analyze and store for future research sleep and sleep disorders related biological and psychological information. It will include sleep physiological measurements and the results of interviews, questionnaires, and laboratory tests. The SRDR will contain sleep related information obtained from healthy subjects and patients with psychiatric, substance abuse, neurological disorders, or any medical conditions associated with sleep disturbances. SRDR data will be made available to current and future IRB-approved investigators associated with this protocol.